Cabozantinib (Phenylene-d4) L-Malate Salt

CAS: 1140909-48-3

Ref. TR-C051502

Produktinformation

• Name: Cabozantinib (Phenylene-d4) L-Malate Salt
• Synonyme: N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide-d4 (2S)-2-Hydroxybutanedioic Acid, Cabozantini-d4 S-Malate, XL 184-d4, (2S)-2-Hydroxybutanedioic acid compd.with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide(1:1), (2S)-2-hydroxybutanedioic acid, Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4- quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1), Cabozantinib L-(-)-Apple Acid, Cabozantinib L-Malate, Cabozantinib Malate, Cometriq, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide mono[(2S)-2-hydroxybutanedioate], N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Xl 184
• CAS: 1140909-48-3

Beschreibung

Applications Cabozantinib-d4 L-Malate Salt, is the labeled analogue of Cabozantinib L-Malate Salt (C051500), which is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis.
References Camp, R., et al.: Cancer, 86, 2259 (1999), Morello, S., et al.: J. Cell Physiol., 189, 285 (2001), Zhang, Y., et al.: Oncogene, 21, 217 (2002), Wells, S., et al.: J. Clin. Oncol., 28, 767 (2010),

• Marke: TRC

Chemische Eigenschaften

• Molekulargewicht: 639.62
• Formel: C₂₈D₄H₂₀FN₃O₅·C₄H₆O₅
• Farbe/Form: Neat
• InChl: InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1/i7D,8D,9D,10D
• InChI Key: InChIKey=HFCFMRYTXDINDK-AWVSFGHMSA-N
• SMILES: O=C(O)C[C@H](O)C(=O)O.[2H]c1c([2H])c(Oc2ccnc3cc(OC)c(OC)cc23)c([2H])c([2H])c1NC(=O)C1(C(=O)Nc2ccc(F)cc2)CC1